PURPOSE: Nanoparticles are able to enhance drug or DNA stability for purposes of optimised deposition to targeted tissues. Surface modifications can mediate drug targeting. The suitability of nanoparticles synthesised out of porcine gelatin, human serum albumin, and polyalkylcyanoacrylate as drug and gene carriers for pulmonary application was investigated in vitro on primary airway epithelium cells and the cell line 16HBE14o-. METHODS: The uptake of nanoparticles into these cells was examined by confocal laser scan microscopy (CLSM) and flow cytometry (FACS). Further the cytotoxicity of nanoparticles was evaluated by an LDH-release-test and the inflammatory potential of the nanoparticles was assessed by measuring IL-8 release. RESULTS: CLSM and FACS experiments showed that the nanoparticles were incorporated into bronchial epithelial cells provoking little or no cytotoxicity and no inflammation as measured by IL-8 release. CONCLUSIONS: Based on their low cytotoxicity and the missing inflammatory potential in combination with an efficient uptake in human bronchial epithelial cells, protein-based nanoparticles are suitable drug and gene carriers for pulmonary application.
PURPOSE: Nanoparticles are able to enhance drug or DNA stability for purposes of optimised deposition to targeted tissues. Surface modifications can mediate drug targeting. The suitability of nanoparticles synthesised out of porcine gelatin, human serum albumin, and polyalkylcyanoacrylate as drug and gene carriers for pulmonary application was investigated in vitro on primary airway epithelium cells and the cell line 16HBE14o-. METHODS: The uptake of nanoparticles into these cells was examined by confocal laser scan microscopy (CLSM) and flow cytometry (FACS). Further the cytotoxicity of nanoparticles was evaluated by an LDH-release-test and the inflammatory potential of the nanoparticles was assessed by measuring IL-8 release. RESULTS: CLSM and FACS experiments showed that the nanoparticles were incorporated into bronchial epithelial cells provoking little or no cytotoxicity and no inflammation as measured by IL-8 release. CONCLUSIONS: Based on their low cytotoxicity and the missing inflammatory potential in combination with an efficient uptake in human bronchial epithelial cells, protein-based nanoparticles are suitable drug and gene carriers for pulmonary application.
Authors: Jeffrey W Card; Darryl C Zeldin; James C Bonner; Earle R Nestmann Journal: Am J Physiol Lung Cell Mol Physiol Date: 2008-07-18 Impact factor: 5.464
Authors: Malgorzata S Cartiera; Katherine M Johnson; Vanathy Rajendran; Michael J Caplan; W Mark Saltzman Journal: Biomaterials Date: 2009-02-20 Impact factor: 12.479
Authors: Claudia B Packhaeuser; Kerstin Lahnstein; Johannes Sitterberg; Thomas Schmehl; Tobias Gessler; Udo Bakowsky; Werner Seeger; Thomas Kissel Journal: Pharm Res Date: 2008-10-08 Impact factor: 4.200
Authors: Jedd M Hillegass; Arti Shukla; Sherrill A Lathrop; Maximilian B MacPherson; Naomi K Fukagawa; Brooke T Mossman Journal: Wiley Interdiscip Rev Nanomed Nanobiotechnol Date: 2010 May-Jun
Authors: J Klier; B Lehmann; S Fuchs; S Reese; A Hirschmann; C Coester; G Winter; H Gehlen Journal: J Vet Intern Med Date: 2015-01 Impact factor: 3.333